Jane Bromund

822 total citations
17 papers, 609 citations indexed

About

Jane Bromund is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jane Bromund has authored 17 papers receiving a total of 609 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in Jane Bromund's work include Cancer Treatment and Pharmacology (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Jane Bromund is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Jane Bromund collaborates with scholars based in United States and United Kingdom. Jane Bromund's co-authors include Coleman K. Obasaju, Ruqin Chen, Joseph Treat, Martin Marciniak, Joan H. Schiller, John F. Gill, Shaker R. Dakhil, Panos Fidias, David Loesch and Alan P. Lyss and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology and Clinical Breast Cancer.

In The Last Decade

Jane Bromund

17 papers receiving 595 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jane Bromund United States	9	467	447	127	85	42	17	609
Joo‐Hang Kim South Korea	10	338 0.7×	310 0.7×	109 0.9×	66 0.8×	51 1.2×	17	445
Kosei Tajima Japan	8	611 1.3×	529 1.2×	150 1.2×	98 1.2×	30 0.7×	15	706
Janusz Milanowski Poland	4	636 1.4×	603 1.3×	174 1.4×	68 0.8×	20 0.5×	11	722
Hernán Carranza Colombia	10	280 0.6×	245 0.5×	131 1.0×	117 1.4×	28 0.7×	36	417
M. Lomas Spain	7	364 0.8×	419 0.9×	94 0.7×	52 0.6×	42 1.0×	23	518
Joseph Burke United States	5	499 1.1×	400 0.9×	98 0.8×	62 0.7×	41 1.0×	7	572
B. E. Johnson United States	12	388 0.8×	359 0.8×	209 1.6×	101 1.2×	22 0.5×	17	534
C. Zhou China	9	551 1.2×	449 1.0×	202 1.6×	153 1.8×	40 1.0×	50	660
Laure Hirsch France	9	246 0.5×	297 0.7×	183 1.4×	116 1.4×	45 1.1×	16	517
Tzu‐Hsiu Tsai Taiwan	13	471 1.0×	372 0.8×	183 1.4×	178 2.1×	41 1.0×	17	611

Countries citing papers authored by Jane Bromund

Since Specialization

Citations

This map shows the geographic impact of Jane Bromund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Bromund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Bromund more than expected).

Fields of papers citing papers by Jane Bromund

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Bromund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Bromund. The network helps show where Jane Bromund may publish in the future.

Co-authorship network of co-authors of Jane Bromund

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Bromund. A scholar is included among the top collaborators of Jane Bromund based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Bromund. Jane Bromund is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Yardley, Denise A., James A. Reeves, Elizabeth Claire Dees, et al.. (2016). Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. Clinical Breast Cancer. 16(6). 471–479.e1. 29 indexed citations

Yardley, Denise A., Paul Richards, James A. Reeves, et al.. (2014). Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC).. Journal of Clinical Oncology. 32(15_suppl). 1035–1035. 16 indexed citations

Borson, R., Graydon Harker, James A. Reeves, et al.. (2012). Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer. 12(5). 322–330. 7 indexed citations

Yardley, Denise A., Cynthia R. Osborne, Paul Richards, et al.. (2012). Interim safety results of eribulin (E) combined with ramucirumab (RAM) in patients (pts) with advanced metastatic breast cancer (MBC).. Journal of Clinical Oncology. 30(27_suppl). 110–110. 1 indexed citations

Schwartzberg, Lee S., Hatem Soliman, Alison Conlin, et al.. (2012). Phase II results of tasisulam-sodium in previously treated patients with metastatic breast cancer.. Journal of Clinical Oncology. 30(27_suppl). 114–114. 1 indexed citations

Brufsky, Adam, Karen Hoelzer, Thaddeus Beck, et al.. (2011). A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer. Clinical Breast Cancer. 11(4). 211–220. 25 indexed citations

Socinski, Mark A., Robert N. Raju, Thomas E. Stinchcombe, et al.. (2010). Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(12). 1963–1969. 33 indexed citations

Raju, Robert N., Mark A. Socinski, Thomas E. Stinchcombe, et al.. (2009). A prospective evaluation of quality of life (QOL) in a phase II trial of pemetrexed (P) plus carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) plus Cb as first-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 27(15_suppl). e19050–e19050. 2 indexed citations

Reynolds, Craig H., Coleman K. Obasaju, Michael J. Schell, et al.. (2009). Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(34). 5808–5815. 138 indexed citations

10.

Hoelzer, Karen L., Adam Brufsky, J. Thaddeus Beck, et al.. (2009). Preliminary results of a randomized phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer. Journal of Clinical Oncology. 27(15_suppl). 1089–1089. 1 indexed citations

11.

Obasaju, Coleman K., Robert N. Raju, Thomas E. Stinchcombe, et al.. (2009). Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 27(15_suppl). 8037–8037. 11 indexed citations

12.

Dudek, Arkadiusz Z., Timothy Larson, Michael McCleod, et al.. (2008). Phase 1/2 Dose Escalating Study of Twice-Monthly Pemetrexed and Gemcitabine in Patients with Advanced Cancer and Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(4). 394–399. 16 indexed citations

13.

Socinski, Mark A., Robert N. Raju, Marcus A. Neubauer, et al.. (2008). Pemetrexed in Relapsed Small-Cell Lung Cancer and the Impact of Shortened Vitamin Supplementation Lead-In Time: Results of a Phase II Trial. Journal of Thoracic Oncology. 3(11). 1308–1316. 20 indexed citations

14.

Fidias, Panos, Shaker R. Dakhil, Alan P. Lyss, et al.. (2008). Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(4). 591–598. 304 indexed citations

15.

Kocs, Darren M., Robert N. Raju, Mark A. Socinski, et al.. (2008). Preliminary results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (ENZ) versus docetaxel (D) + Cb as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 26(15_suppl). 8061–8061. 1 indexed citations

16.

Reynolds, Craig H., Paul Conkling, Donald Richards, et al.. (2007). P2-292: A randomized Phase 3 trial of gemcitabine with or without carboplatin in performance status 2 (PS2) patients with advanced (stage IIIB with pleural effusion or IV) non-small-cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S688–S688. 3 indexed citations

17.

Socinski, Mark A., Robert N. Raju, Donald Richards, et al.. (2007). P1-229: The impact of shortened vitamin supplementation lead-in time before pemetrexed (P) in patients with relapsed small-cell lung cancer (SCLC). Journal of Thoracic Oncology. 2(8). S829–S830. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact